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Abstract
Background: Legionnaires’ disease (LD) is a severe bacterial infection causing pneumonia. Surveillance commonly
underestimates the true incidence as not all cases are laboratory confirmed and reported to public health
authorities. The aim of this study was to present indicators for the impact of LD in Belgium between 2013 and 2017
and to estimate its true burden in the Belgian population in 2017, the most recent year for which the necessary
data were available.
Methods: Belgian hospital discharge data, data from three infectious disease surveillance systems (mandatory
notification, sentinel laboratories and the national reference center), information on reimbursed diagnostic tests
from the Belgian National Institute for Health and Disability Insurance and mortality data from the Belgian statistical
office were used. To arrive at an estimate of the total number of symptomatic cases in Belgium, we defined a
surveillance pyramid and estimated a multiplication factor to account for LD cases not captured by surveillance. The
multiplication factor was then applied to the pooled number of LD cases reported by the three surveillance
systems. This estimate was the basis for our hazard- and incidence-based Disability-Adjusted Life Years (DALYs)
calculation. To account for uncertainty in the estimations of the DALYs and the true incidence, we used Monte
Carlo simulations with 10,000 iterations.
Results: We found an average of 184 LD cases reported by Belgian hospitals annually (2013–2017), the majority of
which were male (72%). The surveillance databases reported 215 LD cases per year on average, 11% of which were
fatal within 90 days after diagnosis. The estimation of the true incidence in the community yielded 2674 (95%
Uncertainty Interval [UI]: 2425–2965) cases in 2017. LD caused 3.05 DALYs per case (95%UI: 1.67–4.65) and 8147
(95%UI: 4453–12,426) total DALYs in Belgium in 2017, which corresponds to 71.96 (95%UI: 39.33–109.75) DALYs per
100,000 persons.
Conclusions: This analysis revealed a considerable burden of LD in Belgium that is vastly underestimated by
surveillance data. Comparison with other European DALY estimates underlines the impact of the used data sources
and methodological approaches on burden estimates, illustrating that national burden of disease studies remain
essential.
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Background
Legionnaires’ disease (LD) is a commonly underdiag-
nosed cause of pneumonia [1]. It is acquired through the
inhalation of water droplets containing bacteria of the
family Legionellaceae, which can multiply within amoeba
and are ubiquitously present in various aquatic environ-
ments. There are over 50 known Legionella species,
nearly half of which have been isolated from human
samples. Legionella pneumophila serotype 1 accounts for
more than 90% of community-acquired LD cases [2]. In
Europe, the age-adjusted overall reported annual inci-
dence of LD is 1.0 to 1.6 cases per 100,000 persons but
varies substantially between countries, which is likely in-
fluenced by their LD detection and reporting capabilities
[3, 4]. The disease predominantly affects males and per-
sons aged above 65 years and is fatal in around 9% of re-
ported cases [3]. Most reported cases occur sporadically
and are community-acquired [3]. LD cannot be clinically
distinguished from pneumonia caused by other agents; a
definite diagnosis therefore requires the confirmation of
the pathogen in specimen of the patient. This necessity
of specific diagnostic tests and their shortcomings have
been suggested to contribute to its frequent underre-
porting by surveillance systems, along with lacking
awareness for the disease by health professionals [5].
Previous studies investigating the burden of LD have
therefore included means to account for cases missed by
surveillance in their analysis [6, 7].
The objectives of this study were to present indicators
that reflect the impact of LD in Belgium between 2013
and 2017 and to estimate the true burden of the disease
in the specific context of the Belgian population in 2017.
Methods
Reference period and population
Different data sources were used to describe and esti-
mate the burden of LD in the Belgian population. We
summarized information on the reported cases, hospital-
izations and deaths due to LD for all years between 2013
and 2017 for which the respective data were available.
For the year 2017, we also estimated the true incidence
of LD in Belgium and calculated the Disability Adjusted
Life Years (DALYs) caused by the disease. This was only
done for 2017, as it was the only year with fully available
data for this purpose after 2016, the year in which the
reimbursement of the urinary antigen (UAg) test was in-
troduced in Belgian hospitals (as described below),
which is believed to have affected the LD detection fre-
quency in the country. Incidence and DALY rates per
100,000 population were calculated based on the Belgian
population on the 1st of January 2017 [8].
This article does not address Pontiac fever, another
clinical manifestation of a Legionella spp. infection that
only has a mild, flu-like course and usually does not
require treatment, as it is not included in the current
case definition for LD by the European Union [9].
Data sources
Hospital discharge data
The hospital discharge data (HDD) are a national and
compulsory database managed by the Belgian Federal
Public Service Health, Food chain safety and Environ-
ment. Since 1991, all hospitals have to report data about
discharge diagnosis, duration of stay and basic demo-
graphic characteristics of all patients. Until the end of
2014, diseases were coded according to the International
Statistical Classification of Diseases and Related Health
Problems, 9th revision (ICD-9). Since 2016, the 10th re-
vision of the ICD is in use. There are no data available
for 2015, the transition period.
To present the number of hospitalized LD cases, we
analyzed all hospital records with a patient discharge
date between 2013 and 2017 and a primary (main) or
secondary diagnosis of LD (ICD-9 code: 482.84 Pneumo-
nia due to Legionnaires’ disease; ICD-10 code: A48.1,
Legionnaires disease).
Furthermore, as part of the estimation of the true inci-
dence of LD in Belgium in 2017 (described below), hos-
pital records with bacterial pneumonia as primary or
secondary diagnosis (ICD-10 codes J13 and J15–J18)
from 2017 were extracted and used to estimate the pro-
portion of LD cases that were not tested for Legionella
spp. and therefore not captured by surveillance.
Belgian surveillance systems for legionnaires’ disease
There are three Belgian surveillance systems that register
diagnosed cases of LD; i.e., mandatory notification
(MN), sentinel laboratories (SL) and the national refer-
ence center (NRC). The surveillance system of SL is
managed by Sciensano, the Belgian Institute of Health.
Sciensano also receives data from the NRC and MN
each year in order to carry out its missions of surveilling
infectious diseases and providing data to the World
Health Organization (WHO) and the European Centre
for Disease Prevention and Control (ECDC).
MN is a competence delegated to the regional author-
ities in Belgium. Doctors are required to report each
confirmed case of LD (following the EU case definition
of LD [9]) to the health inspectorates of one of the three
regions (Flanders, Wallonia or Brussels). The health in-
spectorates then collect demographic information, infor-
mation about the diagnostic test used and risk factors, as
well as other data necessary to identify the source of in-
fection. In 2012, a capture-recapture study (CRS) with
two data sources was performed in Wallonia, which esti-
mated a reporting completeness of 65% of the MN [10].
The SL surveillance system is based on voluntary par-
ticipation by Belgian laboratories. Each participating
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laboratory sends weekly positive diagnoses of a series of
diseases, including LD. For LD, the SL collects demo-
graphic information and reports what diagnostic test
was used. All patients with a positive test for Legionella
spp. are reported, regardless of clinical symptoms. The
surveillance network is estimated to cover around 50%
of the diagnostic tests performed in Belgium [11].
For LD, the NRC consists of a consortium of two la-
boratories that confirm the diagnoses of samples sent by
clinical laboratories and perform more complex exami-
nations (culture, PCR and typing). Cases are reported by
them in accordance with the EU case definition for LD
[9]. The NRC has been established in 2011 [12]. The rate
of reporting completeness of this surveillance source is
unknown for LD.
The data extracted from the three available data
sources for this study are anonymous, but contain infor-
mation about postal code, date of birth and sex of the
patient. These variables were used to identify and re-
move duplicates between the different sources in order
to calculate the unique annual number of ‘reported LD
cases’ in Belgium from 2013 to 2017 that will be used in
the remainder of the manuscript. To avoid mismatches,
cases for which one of the three variables was missing
were not considered in this process.
As part of the estimation of the true incidence of LD,
the completeness of reporting of diagnosed LD cases
was estimated by performing a capture-recapture study
(CRS) with all three data sources for the year 2017, using
a generalized linear model with a log link function and a
Poisson error structure. A more detailed description of
this step can be found in Additional file 1 and the out-
come of the CRS is displayed in Additional file 2. We
also used the data from MN Flanders to ascertain the
proportions of the diagnostic tests used in Belgium (see
Additional file 1), as this information was most complete
from this data source.
Mortality data
The Belgian statistical office, Statbel, compiles demo-
graphic information and information about the causes of
death of all deceased persons in Belgium. Using the vari-
ables birth date, postal code and sex, we combined this
dataset with the data on reported LD cases to find cases
that died within 90 days after diagnosis in each year be-
tween 2013 and 2016 (data for 2017 were not available).
The threshold of 90 days was chosen as the authors be-
lieved that most deaths connected to LD would have oc-
curred within this period and that deaths reported
thereafter may have more likely been unrelated to the
infection. The case fatality ratios were calculated by div-
iding the number of deaths we found with this approach
by the total number of reported cases for each year.
The Belgian National Institute for health and disability
insurance
The Belgian National Institute for Health and Disability
Insurance (NIHDI) started reimbursing UAg tests for
LD in hospitals in September 2016. For the estimation of
the true incidence of LD in Belgium in 2017 (see below),
we used the number of UAg tests that have been reim-
bursed in 2017.
More information about the institutions that provided
the data can be found in Additional file 3.
True incidence and disability-adjusted life years (DALYs)
True incidence of legionnaires’ disease
LD incidence was estimated using a pyramid reconstruc-
tion approach in which the different steps necessary for
the reporting of a symptomatic LD infection in the com-
munity by a laboratory-based surveillance system are de-
fined (Fig. 1). The cases captured by surveillance (top of
the pyramid) are only those that seek medical care, get
diagnosed correctly and are properly reported. To arrive
at an estimate of all symptomatic cases in the commu-
nity (bottom of the pyramid), a multiplication factor
(MF) to account for cases lost to reporting at each level
of the pyramid is required [13].
We assessed the probability of transitioning from the
lowest to the highest level of the pyramid for 2017 by
using available Belgian data and information from the
literature when no Belgian data were available. Add-
itional file 1 shows the data and data sources we used, as
well as a more detailed description of the five steps in
which we accounted for underreporting (at the health-
care level) and under-ascertainment (at the community
level) of LD.
Disability-adjusted life years (DALYs)
We used the DALY indicator to quantify the health bur-
den of LD in Belgium. DALYs combine the mortality
(Years of Life Lost, YLL) and morbidity (Years Lived
with Disability, YLD) impact caused by a disease into a
single measure, enabling the comparison of its burden
between countries or regions and to other diseases. A
more detailed description of the properties and calcula-
tion of this indicator can be found elsewhere [14]. To
calculate the YLL, we used the reference life table from
the 2017 Global Burden of Disease study which assigns a
life expectancy of 87.9 years at birth to both men and
women [15]. Social weighting functions were not
included.
A disease model or outcome tree displays all possible
manifestations of a disease that are considered in the
DALY calculation. There are different methodological
possibilities for constructing it. As recommended for
assessing the burden of infectious diseases, we used inci-
dence data and the hazard-based approach, where the
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infection constitutes the root of the outcome tree
[16, 17].
We used the outcome tree previously defined in the
course of the Burden of Communicable Diseases in Eur-
ope (BCoDE) project [18] and complemented it with
data from the disease model from a Dutch study ([7],
Online Appendix). The case fatality ratios for compli-
cated cases and cases admitted to the intensive care unit
were taken from the BCoDE outcome tree, while, in line
with the Dutch study, the ratio for uncomplicated cases
was set to 0%. We verified the appropriateness of these
parameters in the context of this analysis by comparing
their weighted average (8.5%; weighted for the respective
proportions of disease severity, which are shown in Add-
itional file 4), to the Belgium-specific case fatality ratios
we estimated for the years 2013 to 2016 (see Table 1),
which were of similar magnitude. The final disease
model is displayed in Additional file 4.
Data analysis and uncertainty
To account for uncertainty in the estimation of the true
incidence, we fitted a distribution to each transition
probability from one level of the surveillance pyramid to
the next and performed Monte Carlo simulations (10,
Fig. 1 Surveillance pyramid for Legionnaire’s disease (LD) in Belgium in 2017. Illustration of how underreporting (UR; healthcare-level) and under-
ascertainment (UA; community-level) affect the reported incidence of LD. The MFs account for cases lost to surveillance (reported incidence) at
leach level. They were derived using this equation: MF = 1/x, where x is the probability of transitioning from one level to the next higher one we
determined for the respective level based on available Belgian data and literature (see Additional file 1). MF: multiplication factor; CRS: capture-
recapture study; UI: Uncertainty Interval
Table 1 Presentation of the number of reported LD cases, the number of deaths among them and information about hospitalized
LD cases in Belgium, 2013 to 2017
2013 2014 2015 2016 2017 Mean
Reported LD casesa 190 186 191 227 280 215
Deaths among reported LD casesb 26 23 17 21 n.a. 22
Case fatality ratio (95%CI) 14% (9–19%) 12% (8–17%) 8.9% (5–13%) 9.3% (5–13%) n.a. 11% (9–13%)
Hospitalized LD casesc 155 163 n.a. 180 232 184
Median duration of stay in days (min–max) 13 (0–130) 9 (0–172) n.a. 9 (0–227) 9 (1–78) 10
Proportion of males 66% 79% n.a. 71% 72% 72%
Proportion of cases aged≥ 65 years 42% 40% n.a. 41% 49% 43%
LD Legionnaires’ disease, CI Confidence interval, ICD International Statistical Classification of Diseases and Related Health Problems, n.a. No data available
aCombined cases from the national reference center, mandatory notification and sentinel laboratories; duplicates excluded based on overlapping birth dates,
postal codes and gender
bStatistics Belgium death certificate data linked with data of the reported LD cases based on overlapping birth dates, postal codes and gender. Deaths within 90
days after diagnosis were included
cHospitalized patients with a primary or secondary diagnosis of LD (ICD-9 code 482.84; ICD-10 code A48.1) as reported by the hospital discharge data
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000 iterations) to arrive at 95% uncertainty intervals
(UIs) at each step of the pyramid (defined as the 2.5th
and 97.5th percentile of the distribution of random
values). We then multiplied the results to get an overall
rate of reporting completeness and derive an overall 95%
UI.
The level-specific and overall MFs, as well as their
95%UIs, were calculated as the inverses of the respective
rates of reporting completeness. They are displayed next
to the surveillance pyramid in Fig. 1.
To assess the robustness of the MF, we performed a
variable importance analysis (sensitivity analysis) to
quantify the contribution of each uncertain input vari-
able to the overall uncertainty of the end result. Specific-
ally, we calculated partial correlation coefficients to
quantify the correlation between a given input and the
output, when adjusting for all other input variables. This
approach is not affected by possible interactions between
input variables, in contrast to standardized regression
coefficients.
Additional file 1 summarizes the model input and data
sources we used to estimate the true incidence of LD in
Belgium. The analyses were performed in R 3.6.1 [19],
the R script can be found in Additional file 5.
The capture-recapture study (CRS) and the calculation
of the DALYs were performed in SAS version 9.3 (SAS
Institute Inc., Cary, NC, USA). We also used Monte
Carlo simulations to account for the uncertainty in dis-
ability weights, disease durations and risks to develop
the health outcomes used in the DALY calculation. The
distributions we used for this step are shown in
Additional file 4.
Results
Reported incidence, hospitalization and mortality
Table 1 displays information on LD patients reported in
the community and by hospitals in Belgium and LD-
associated mortality for all years with available data be-
tween 2013 and 2017. Overall, the numbers of reported
and hospitalized LD cases showed increasing trends, es-
pecially after 2015. Most cases reported by hospitals
were male (72%) and over 40% were aged 65 years or
older. LD patients stayed in the hospitals for a median
duration of 13 days in 2013 and 9 days in the years with
available data thereafter, with total days ranging from 0
to up to 227 days. 11% of reported LD cases died within
90 days after diagnosis.
True incidence
In 2017, the number of reported LD cases was 280 (2.47
reported cases per 100,000 inhabitants). The MF be-
tween cases ascertained through surveillance and cases
in the community was estimated at 9.55 (95%UI: 8.66–
10.59) (see Fig. 1). Thus, the estimated true incidence of
LD was 2674 (95%UI: 2425–2965) cases in 2017, which
corresponds to 23.62 (95%UI: 21.42–26.19) cases per
100,000 persons.
Figure 2 shows the results of the variable importance
analysis, sorted by decreasing order of importance. The
largest partial correlation coefficients were found for the
test sensitivity, followed by the proportion of hospital-
ized LD cases, the proportion of cases that seeked
healthcare, and the proportion of diagnosed cases that
were reported.
Disability-adjusted life years (DALYs)
LD caused 810 YLD (95%UI: 465–1195) and 7336 YLL
(95%UI: 3988–11,231) in Belgium in 2017, amounting to
8147 (95%UI: 4453–12,426) DALYs in total or 71.96
(95%UI: 39.33–109.75) DALYs per 100,000 persons. The
individual burden was 3.05 (95%UI: 1.67–4.65) DALYs
per LD case, 2.74 (95%CI: 1.49–4.20) of which were at-
tributable to YLL and 0.30 (95%CI: 0.17–0.45) to YLD.
Discussion
This study was conducted to estimate the DALYs caused
by LD in Belgium in 2017 and to present different indi-
cators for the burden of the disease for years between
2013 and 2017, depending on the availability of data.
The surveillance data showed an increase of the re-
ported number of LD cases after 2015. This may be con-
nected to factors such as climate change or population
ageing, which have been suggested to contribute to the
generally observed rise in reported LD incidence in Eur-
ope [4]. It might, however, also be explained by a rising
awareness for the disease among health professionals
and improved access to the UAg test following the intro-
duction of its reimbursement in Belgian hospitals in Sep-
tember of 2016.
In line with previous observations [3, 4], persons with
male sex were predominantly affected by LD (72%). This
sexual dimorphism has also been reported for most
other infections of the lower respiratory tract and has
been suggested to be to be related biological factors,
such as differing levels of sex hormones, which are
known to impact immune activation. Women, have, for
example, higher levels of the immune-stimulating sex
hormone estradiol than men while they produce less tes-
tosterone, which has anti-inflammatory properties. Fac-
tors, such as anatomical differences or differences in
lifestyles and socioeconomic statuses between the sexes,
may also contribute to their unequal vulnerability to
lower respiratory infections [20, 21].
Our DALY calculation revealed a considerable burden
which was mainly due to premature mortality, with 3.05
DALYs per case (95%UI: 1.67–4.65) and 8147 (95%UI:
4453–12,426) total DALYs per year, corresponding to
71.96 (95%UI: 39.33–109.75) DALYs per 100,000
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population in 2017. To put this result into perspective,
the total burden of foodborne diseases in European
countries with a low mortality, such as Belgium, was es-
timated at 41 DALYs per 100,000 population in 2010
[22].
There are two other European studies that also esti-
mated the true incidence of LD in the community and
used it for DALY calculations. One assessed the burden
of infectious diseases in the countries of the European
Union (EU) and the European Economic Area (EEA)
from 2009 to 2013 in the frame of the BCoDE project,
and the other one estimated the burden specifically for
the Netherlands from 2007 to 2011 [6, 7].
Their results only partly agree with our estimates. Esti-
mates of DALYs per case are largely determined by the
parameters of the disease model. The proportion of fatal
cases is especially influential for acute and severe dis-
eases such as LD. As our outcome tree was very similar
to the one used by the BCoDE study, our DALYs per
case estimate of 3.05 was comparable to their estimate
of 3.04 DALYs per case. The Dutch study, however, as-
sumed a higher proportion of non-hospitalized cases
with a negligible risk of dying, thus, their estimation of
the number of DALYs per case (0.97 DALYs per case)
was lower than ours. DALYs on the population-level are
dependent on both the disease model and the estimated
disease incidence [16]. The comparability of our results
to the previous studies is therefore considerably influ-
enced by the underlying estimation of the true incidence
of LD in the population. Our estimate of the true
incidence of LD was similar to the one by the Dutch
study (27 cases per 100,000 population per year; rate cal-
culated based on the mean population size of the
Netherlands 2007–2011 [23]) but was around seven
times higher than the estimate for the EU/EAA region
by the BCoDE study (3.4 cases per 100,000 per year). As
a result, our estimation of the population-level DALYs
was substantially higher than in the BCoDE study (71.96
vs. 10.3 DALYs per 100,000 people per year, respect-
ively), even though the number of DALYs per case was
similar.
Our higher estimation of the population-level DALYs
in Belgium in 2017 may be related to a real increase in
LD incidence in Europe since the study period of the
BCoDE study [4]. It is, however, important to notice that
differences in methodology, data sources and assump-
tions have a major impact on the estimated burden of
LD. The BCoDE project aimed at assessing the disease
burden in Europe, thus, they pooled countries in three
groups depending on the quality of their surveillance
systems for which they applied three different MFs that
were based on studies from France and Germany ([6],
Additional file 3). We believe that by deriving our MF
based on the surveillance pyramid, utilizing specific Bel-
gian data and information from the literature, our esti-
mate most appropriately approximates the situation in
this country. Our results are strengthened by their com-
pliance with previous studies investigating the rate of LD
among persons with community-acquired pneumonia
(CAP), such as the German CAPNEZ study, which
Fig. 2 Variable Importance Analysis of the variables included in the estimation of the multiplication factor to account for underreporting and
under-ascertainment of LD in Belgium in 2017. UAg: Urinary Antigen; PCR: Polymerase Chain Reaction
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found that 3.8% of CAP cases were attributable to Le-
gionella spp. infections [24]. When compared to the
number of pneumonia cases reported by the HDD, our
estimated true incidence of LD accounted for around
3.3% of them.
Nevertheless, our assessment of the true incidence of
LD has several limitations.
First, one of the surveillance databases we accessed to
ascertain the number of reported LD cases in 2017, the
SL, does not include pneumonia in the definition of LD
cases, but reports all patients who have been tested posi-
tive for Legionella spp., regardless of the symptoms. This
may have led to an overestimation of the number of re-
ported cases and, in turn, in the estimated true incidence
of LD. However, given that pneumonia is included in the
official case definition of LD by the EU [9], physicians
usually only order a test for Legionella spp. if the patient
presents with this symptom. Furthermore, only 16% of
reported cases were solely reported by the SL and not by
one of the two other surveillance databases (see Add-
itional file 2). Therefore, this limitation is not expected
to have influenced the results greatly.
Second, in absence of more detailed information on
the clinical picture of pneumonia patients in Belgium,
we assumed that patients suffering from LD have the
same chance of being tested for Legionella spp. as all pa-
tients hospitalized with bacterial pneumonia (see Add-
itional file 1). While, in theory, pneumonia is the only
clinical criterion for a LD diagnosis [9], the testing rate
among actual LD patients might still be higher than
among bacterial pneumonia cases. This may have led to
an overestimation of the incidence of LD at the commu-
nity level, especially considering that this step contrib-
uted most to the overall estimated incidence (44% of
overall MF).
Third, the HDD is an administrative tool built for fi-
nancial purposes and does not collect data for epidemio-
logical use. The diagnosis accuracy and the consistency
in disease coding may therefore be questioned. Using
this data to estimate the testing rate for Legionella spp.
might have led to an over- or underestimation of the
true incidence of LD.
Fourth, we assumed that all cases of LD reported to
one of the Belgian surveillance databases were hospital-
ized. This hypothesis was supported by different Belgian
experts (health inspectors, NRC) and by data from MN
in Flanders but since the information was not available
from all sources, it is possible that some of the reported
LD cases were diagnosed outside of hospitals. In this
case, the MF to account for cases not hospitalized may
have been overestimated while the MF to adjust for
cases not tested for Legionella spp. might have been too
low, considering that the reimbursement of the UAg
only applies to hospitals.
Finally, as we did not have information on the
hospitalization rate among LD patients in Belgium, we
used the rate defined in the outcome tree of the BCoDE
project as an approximation even though it might not
completely apply to the Belgian context.
The results of the variable importance analysis for the
variables included in the estimation of the true incidence
of LD indicated that the sensitivity of the UAg test, the
proportion of hospitalized LD cases, the proportion of
cases seeking medical help and the reporting complete-
ness of diagnosed cases had the largest influence on the
overall uncertainty of the total MF (see Fig. 2). Future
research should focus on these elements to reduce un-
certainties and obtain more precise LD burden
estimates.
The DALY calculation itself was strengthened by our
usage of the outcome tree previously defined in the
course of the BCoDE project, which we complemented
with additional parameters from the disease model of
the Dutch study. Furthermore, to validate the case fatal-
ity ratios defined in this outcome tree, which were highly
influential on the burden estimation, we compared them
to the Belgium-specific case fatality ratio we estimated
for the years 2013 to 2016 based on LD surveillance and
overall mortality data (see Table 1). This validation con-
stitutes another strength of the DALY calculation. A
limitation was, however, that we applied the same dis-
ease durations and case fatality ratios to both genders
and all age groups, even though in reality differences are
to be expected. This might have led to an overestimation
of the YLL.
Further research is necessary to overcome these data
gaps as they may have an important impact on the final
DALY estimations.
Conclusion
This study was the first assessment of the true burden of
LD in Belgium. We found LD to cause a substantial
health burden in Belgium that is highly underestimated
by existing surveillance systems that are based on la-
boratory confirmed cases. The differences between our
results and the outcomes of the BCoDE study illustrate
the impact of the used data sources and methodological
approaches on the final estimates. Therefore, national
burden of disease studies remain an essential comple-
ment to international studies.
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